[go: up one dir, main page]

AU2024263322A1 - Compositions and methods for treating post-traumatic stress disorder - Google Patents

Compositions and methods for treating post-traumatic stress disorder

Info

Publication number
AU2024263322A1
AU2024263322A1 AU2024263322A AU2024263322A AU2024263322A1 AU 2024263322 A1 AU2024263322 A1 AU 2024263322A1 AU 2024263322 A AU2024263322 A AU 2024263322A AU 2024263322 A AU2024263322 A AU 2024263322A AU 2024263322 A1 AU2024263322 A1 AU 2024263322A1
Authority
AU
Australia
Prior art keywords
compositions
methods
stress disorder
traumatic stress
treating post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024263322A
Inventor
Alfred KAYE
John KRYSTAL
Christopher PITTENGER
Axel F. ROSADO
Abigail YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
US Department of Veterans Affairs
Original Assignee
Yale University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, US Department of Veterans Affairs filed Critical Yale University
Publication of AU2024263322A1 publication Critical patent/AU2024263322A1/en
Assigned to YALE UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS reassignment YALE UNIVERSITY Amend patent request/document other than specification (104) Assignors: YALE UNIVERSITY
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2024263322A 2023-04-28 2024-04-26 Compositions and methods for treating post-traumatic stress disorder Pending AU2024263322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363499089P 2023-04-28 2023-04-28
US63/499,089 2023-04-28
PCT/US2024/026542 WO2024226995A1 (en) 2023-04-28 2024-04-26 Compositions and methods for treating post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
AU2024263322A1 true AU2024263322A1 (en) 2025-11-13

Family

ID=93257132

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024263322A Pending AU2024263322A1 (en) 2023-04-28 2024-04-26 Compositions and methods for treating post-traumatic stress disorder

Country Status (2)

Country Link
AU (1) AU2024263322A1 (en)
WO (1) WO2024226995A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020258086A1 (en) * 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
TW202304423A (en) * 2021-04-01 2023-02-01 美商泰仁生物科學公司 Methods and compositions relating to psychedelics and serotonin receptor modulators
IL309953A (en) * 2021-07-07 2024-03-01 Arcadia Medicine Inc Psychoactive compounds are safer
EP4398871A1 (en) * 2021-09-08 2024-07-17 Cybin IRL Limited Combination drug therapies
WO2023049480A1 (en) * 2021-09-25 2023-03-30 Alexander Shulgin Research Institute Substituted phenylalkylamines
IL319372A (en) * 2022-09-06 2025-05-01 Hadasit Med Res Service Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Also Published As

Publication number Publication date
WO2024226995A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
EP4352079A4 (en) Compositions and methods for treating neurofibromatic disorders
EP4096675A4 (en) Compositions and methods for treating long covid
EP4340836A4 (en) Methods and compositions for treating neurological conditions
AU2021372482A9 (en) Compositions and methods for treating hematopoietic malignancy
AU2024263322A1 (en) Compositions and methods for treating post-traumatic stress disorder
CA3290472A1 (en) Compositions and methods for treating post-traumatic stress disorder
EP4157260A4 (en) Compositions and methods for treating headaches
EP4294793A4 (en) Compositions and methods for treating tauopathies
EP4175978A4 (en) Compositions and methods for treating crp-mediated diseases
EP4522159A4 (en) Compositions and methods for treating epilepsy
CA3278586A1 (en) Compositions and methods for treating alpha-synucleinopathies
AU2024322388A1 (en) Methods and compositions for treating ctnnb1-associated disorders
HK40102681A (en) Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
CA3278656A1 (en) Methods and compositions for treating hsd-1-mediated disorders
AU2022903123A0 (en) Compositions and methods for treating disorders
HK40108610A (en) Compositions and methods for treating neurofibromatic disorders
CA3278829A1 (en) Compositions and methods for treating cystitis
HK40111177A (en) Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
HK40107542A (en) Methods and compositions for treating epilepsy
HK40110376A (en) Compositions and methods for treating neurofibromatic disorders
HK40092865A (en) Compositions and methods for treating epilepsy
HK40092865B (en) Compositions and methods for treating epilepsy
HK40090735A (en) Methods and compositions for treating epilepsy
HK40085044A (en) Compositions and methods for treating obsessive-compulsive disorder
HK40089718A (en) Methods and compositions for treating multiple sclerosis

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Free format text: FORMER NAME(S): YALE UNIVERSITY

Owner name: YALE UNIVERSITY

Free format text: FORMER NAME(S): YALE UNIVERSITY